Clarus Therapeutics Holdings, Inc. (CRXT) SEC Filing 8-K Material Event for the period ending Wednesday, August 31, 2022

Clarus Therapeutics Holdings, Inc.

CIK: 1817944 Ticker: CRXT

View differences made from one to another to evaluate Clarus Therapeutics Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Clarus Therapeutics Holdings, Inc..


Assess how Clarus Therapeutics Holdings, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Clarus Therapeutics Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Clarus Therapeutics Holdings, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CRXT
CIK: 1817944
Form Type: 8-K Corporate News
Accession Number: 0001213900-22-054293
Submitted to the SEC: Tue Sep 06 2022 5:21:24 PM EST
Accepted by the SEC: Tue Sep 06 2022
Period: Wednesday, August 31, 2022
Industry: Biological Products No Disgnostic Substances
  1. Bankruptcy or Receivership
  2. Event for Officers
  3. Financial Exhibit
  4. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: